ライフサイエンスコーパス: Janus kinase 3

1 We reported previously that Janus kinase 3, a non-receptor tyrosine kinase, plays a

2 rotein, secreted frizzled-related protein 2, Janus kinase 3, and neutral sphingomyelinase 2 proteins

3 els trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling.

4 tion of STAT3 involves the tyrosine kinases, Janus Kinase-3 as well as Src kinase, whereas the Serine

5 orts, the nonreceptor tyrosine kinase, Jak3 (Janus kinase 3), does not regulate phosphorylation of vi

6 ations are usually absent in the SCID-X1 and Janus kinase 3 forms of SCID and greatly reduced in aden

7 A selective inhibitor of Janus kinase 3 has now been generated and is effective f

8 A selective inhibitor of Janus kinase 3 has now been generated and likely represe

9 IL-2 receptor gamma chain/Janus kinase 3/IL-7 receptor-deficient SCID, myeloablati

10 IL-2 receptor gamma chain/Janus kinase 3/IL-7 receptor-deficient SCID, myeloablati

11 A on Tyr(694) both in vitro and in vivo in a Janus kinase 3-independent fashion.

12 -beta-induced Treg development, and inhibits Janus kinase 3-induced STAT5 phosphorylation, a transcri

13 vide adequate immunosuppression, whereas the Janus kinase 3 inhibitor tofacitinib's success in the tr

14 In an effort to identify novel Janus kinase 3 inhibitors, a sequential focused screenin

15 ing is well known to regulate lymphopoiesis, Janus kinase 3 (JAK3) also plays a critical role in prom

16 Phosphorylation of Janus kinase 3 (JAK3) and signal transducers and activat

17 Mutations in Janus kinase 3 (JAK3) are a cause of severe combined imm

18 tlecitinib, the development of inhibitors of Janus kinase 3 (JAK3) around a putative pyrrolopyrimidin

19 e intermediate domain has been implicated in Janus kinase 3 (JAK3) association and activation.

20 SGs was prevented through the activation of Janus kinase 3 (JAK3) by the vitamin K3 analog menadione

21 yromonas gingivalis enhances the activity of Janus kinase 3 (JAK3) in innate immune cells, and subseq

22 es and tyrosine phosphorylation of STAT6 and Janus kinase 3 (JAK3) in NK and T cells.

23 se, p38 kinase, or phosphoinositol 3-kinase, Janus kinase 3 (JAK3) inhibition produced a significant

24 emistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550).

25 NK cells on SIV infection, use was made of a Janus kinase 3 (JAK3) inhibitor that has previously been

26 sus-host disease (GVHD) prophylaxis with the Janus kinase 3 (JAK3) inhibitor WHI-P131/JANEX-1 on the

27 Janus kinase 3 (Jak3) is a cytoplasmic tyrosine (Tyr) ki

28 Janus kinase 3 (Jak3) is a non-receptor tyrosine kinase

29 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e

30 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e

31 We report here that Janus kinase 3 (Jak3) is a primary response gene for int

32 Janus kinase 3 (Jak3) is a tyrosine kinase expressed in

33 irement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinica

34 Although constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the me

35 Janus kinase 3 (JAK3) mediates signal transduction from

36 ling pathway mutations, including activating Janus kinase 3 (JAK3) mutations, were detected.

37 cy (SCID) patients who exhibited 9 different Janus kinase 3 (JAK3) mutations.

38 microarray-based analyses and showed reduced Janus kinase 3 (JAK3) phosphorylation upon activation.

39 Janus kinase 3 (Jak3) plays a central role in the transd

40 mitogen-activated protein kinase (MAPK), and Janus kinase 3 (JAK3) signaling are necessary for F. tul

41 The Janus kinase 3 (JAK3) tyrosine kinase is mutated in 10%

42 r of cell lines, and the results showed that Janus kinase 3 (JAK3) was with reduced expression in the

43 Janus kinase 3 (JAK3), a member of the Janus family prot

44 ession of a catalytically inactive mutant of Janus kinase 3 (Jak3), and increased in 32D/c-Met cells

45 L7 cells by IL-7 leads to phosphorylation of Janus kinase 3 (JAK3), signal transducer and activator o

46 genesis of colon cancer, nor has the role of Janus kinase 3 (JAK3), the physiological activator of ST

47 phospholipase D2 (PLD2) is under control of Janus kinase 3 (JAK3), which mediates chemotaxis.

48 lso report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating P

49 eficiency (SCID) can be caused by defects in Janus kinase 3 (JAK3)-dependent cytokine signaling pathw

50 nt mutations all resulted in abnormal B-cell Janus kinase 3 (JAK3)-dependent interleukin-2 (IL-2)-ind

51 receptor common gamma chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T c

52 ctions during obesity are because of loss of Janus kinase 3 (JAK3)-mediated tyrosine phosphorylation

53 he IL-2R-associated protein tyrosine kinase, Janus kinase 3 (Jak3).

54 ), DNA-dependent protein kinase (prkdc), and janus kinase 3 (jak3).

55 mmac) cytokine-receptor-induced signaling by Janus kinase 3 (Jak3)/stimulators and activators of tran

56 Janus kinase-3 (JAK3) deficiency has recently been ident

57 We report that Janus kinase 3 plays a role in mast cell-mediated bacter

58 rine systems that in turn activate the Jak3 (Janus kinase 3)/STAT5 (signal transducers and activators